Table 2 Baseline characteristics of study patients
Omarigliptin N = 2100 | Placebo N = 2102 | |
|---|---|---|
Age, years | 63.7 ± 8.5 | 63.6 ± 8.5 |
Male, n (%) | 1461 (69.6) | 1487 (70.7) |
Race, n (%) | ||
White | 1707 (81.3) | 1709 (81.3) |
Asian | 234 (11.1) | 221 (10.5) |
Black | 73 (3.5) | 87 (4.1) |
Multi-racial | 67 (3.2) | 67 (3.2) |
American Indian/Alaska Native | 13 (0.6) | 12 (0.6) |
Native Hawaiian or Other Pacific Islander | 6 (0.3) | 6 (0.3) |
Ethnicity, n (%) | ||
Not Hispanic or Latino | 1813 (86.3) | 1814 (86.3) |
Hispanic or Latino | 267 (12.7) | 266 (12.7) |
Not reported | 13 (0.6) | 10 (0.5) |
Unknown | 7 (0.3) | 12 (0.6) |
Body weight, kg | 89.0 ± 18.5 | 89.6 ± 18.8 |
BMI, kg/m2 | 31.2 ± 5.5 | 31.4 ± 5.6 |
Geographic region | ||
North America | 431 (20.5) | 450 (21.4) |
Europe | 1166 (55.5) | 1169 (55.6) |
Latin America | 140 (6.7) | 144 (6.9) |
Asia | 201 (9.6) | 180 (8.6) |
Othera | 162 (7.7) | 159 (7.6) |
HbA1c, % | 8.0 ± 0.9 | 8.0 ± 0.9 |
Duration of diabetes, years | 12.0 ± 7.6 | 12.1 ± 8.0 |
eGFR (mL/min/1.73 m2) | 85.7 ± 24.5 | 86.6 ± 25.5 |
History of congestive heart failure | 341 (16.2) | 300 (14.3) |
History of hypertension | 1998 (95.1) | 2010 (95.6) |
Cigarette smoking status | ||
Current | 301 (14.3) | 305 (14.5) |
Former | 825 (39.3) | 815 (38.8) |
Never | 974 (46.4) | 981 (46.7) |
Unknown | 0 (0.0) | 1 (0.0) |
Prior AHA therapy | ||
Insulin | 769 (36.6) | 699 (33.3) |
Metformin | 1646 (78.4) | 1606 (76.4) |
Sulfonylurea | 817 (38.9) | 826 (39.3) |
SGLT2 inhibitor | 4 (0.2) | 4 (0.2) |
Thiazolidinedione | 24 (1.1) | 21 (1.0) |
Other | 55 (2.6) | 55 (2.6) |
None | 71 (3.4) | 84 (4.0) |